Key Points
- Guardant Health director Medina Manuel Hidalgo sold 1,000 shares on May 28 at an average price of $130.06, for proceeds of $130,060. After the sale, he held 639 shares, cutting his ownership by 61.01%.
- This was not the director’s only recent sale; Hidalgo also sold 1,250 shares on May 20 and 1,300 shares on March 6, indicating a pattern of insider selling.
- Analysts remain broadly positive on GH, with 19 Buy ratings and an average “Moderate Buy” rating, while the stock has risen to near its 52-week high of $133.97.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Medina Manuel Hidalgo sold 1,000 shares of Guardant Health stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $130.06, for a total transaction of $130,060.00. Following the sale, the director directly owned 639 shares of the company's stock, valued at approximately $83,108.34. This trade represents a 61.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Medina Manuel Hidalgo also recently made the following trade(s):
- On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The stock was sold at an average price of $107.09, for a total transaction of $133,862.50.
- On Friday, March 6th, Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00.
Guardant Health Price Performance
Shares of NASDAQ:GH opened at $129.69 on Friday. The company's fifty day moving average price is $95.08 and its 200 day moving average price is $99.94. Guardant Health, Inc. has a 12 month low of $38.03 and a 12 month high of $133.97. The firm has a market capitalization of $17.20 billion, a P/E ratio of -38.26 and a beta of 1.48.
Analyst Upgrades and Downgrades
GH has been the subject of several research reports. Wells Fargo & Company boosted their target price on Guardant Health from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, February 20th. Robert W. Baird started coverage on Guardant Health in a report on Tuesday, February 17th. They issued an "outperform" rating and a $120.00 price objective for the company. TD Cowen reissued a "buy" rating on shares of Guardant Health in a report on Thursday, May 21st. Canaccord Genuity Group increased their price objective on Guardant Health from $125.00 to $135.00 and gave the company a "buy" rating in a report on Friday, February 20th. Finally, Citigroup increased their price objective on Guardant Health from $135.00 to $150.00 and gave the company a "buy" rating in a report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Guardant Health currently has an average rating of "Moderate Buy" and an average target price of $129.79.
Get Our Latest Stock Report on Guardant Health
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of GH. AQR Capital Management LLC increased its stake in Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company's stock valued at $3,012,000 after purchasing an additional 25,831 shares during the period. Empowered Funds LLC acquired a new position in Guardant Health in the first quarter valued at $274,000. Sei Investments Co. increased its stake in Guardant Health by 15.8% in the second quarter. Sei Investments Co. now owns 77,308 shares of the company's stock valued at $4,023,000 after purchasing an additional 10,538 shares during the period. The Manufacturers Life Insurance Company increased its stake in Guardant Health by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company's stock valued at $32,922,000 after purchasing an additional 54,284 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Guardant Health by 56.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company's stock valued at $5,800,000 after purchasing an additional 40,209 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
